Loading stock data…
TMCI
$3.73+0.20 (+5.67%)
After Hours$3.76+0.03 (+0.80%)· Last close Jun 9
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Treace Medical Concepts, Inc. in the Healthcare sector is trading at $3.73 with a market capitalization of $226M. Wall Street consensus targets $4.00 (3 analysts), implying a +7.2% move over the next 12 months. The stock is currently 52% below its 52-week high of $7.78, remaining 6.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +7.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$3.73
Potential Downside
0%
Whystock Fair Value$3.73
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stab...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$225.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.11
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-67.56%
Volume
Today's trading volume
363,920
Recent News
Treace Medical (TMCI) Q4 2025 Earnings Transcript
John and Mark will discuss our fourth quarter financial results and 2026 outlook. Before we begin, we would like to remind you that it is our intent that all forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. Any statements that relate to expectations or predictions of future events and market trends as well as our estimated results or performance are forward-looking statements.
Treace Medical (TMCI) Q1 2026 Earnings Transcript
Before we begin, we would like to remind you that it is our intent that all forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. Any statements that relate to expectations or predictions of future events, market trends as well as our estimated results or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions.
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks
The market has climbed 1.5% in the last 7 days and is up 26% over the last 12 months, with earnings forecast to grow by 17% annually. While the term 'penny stock' might seem outdated, these investments still offer potential value by focusing on smaller or newer companies with strong financials. In this article, we explore three penny stocks that demonstrate financial strength and could present opportunities for investors seeking hidden value in quality companies.
Treace Medical Concepts Inc (TMCI) Q1 2026 Earnings Call Highlights: Navigating Revenue ...
Despite a 10% revenue drop, Treace Medical Concepts Inc (TMCI) focuses on new product adoption and strategic growth to overcome market challenges.
Treace Medical Concepts Q1 Earnings Call Highlights
Treace Medical Concepts (NASDAQ:TMCI) reaffirmed its full-year 2026 revenue outlook after reporting a first-quarter revenue decline, as management said new product adoption is helping drive procedure volume momentum despite pricing and mix headwinds. On the company’s first-quarter earnings call, Ch